Literature DB >> 24177605

New insights in the pathogenesis of type 1 and type 2 lepra reaction.

Deepika Pandhi1, Namrata Chhabra.   

Abstract

In the current scenario of leprosy elimination, lepra reactions (LRs) remain a major persistent problem. Type 1 LR (T1LR) and type 2 LR (T2LR) are the major causes of nerve damage and permanent disabilities. The immunopathogenesis of LR have recently become an important field of research, since it may provide the relevant targets for the early detection and control of these episodes. Presently, there are no uniformly acceptable laboratory markers for LR. Genetic and serum markers in human host may predict susceptibility to reactions as well as progression of nerve damage in leprosy. Therefore, a deeper understanding of the molecular mechanisms involved in LR may provide a rational strategy for early diagnosis and prevention of the catastrophic consequences of LR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24177605     DOI: 10.4103/0378-6323.120719

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN: 0378-6323            Impact factor:   2.545


  14 in total

1.  Development of Type 2, But Not Type 1, Leprosy Reactions is Associated with a Severe Reduction of Circulating and In situ Regulatory T-Cells.

Authors:  Ana Paula Vieira; Maria Ângela Bianconcini Trindade; Carla Pagliari; João Avancini; Neusa Yurico Sakai-Valente; Alberto José da Silva Duarte; Gil Benard
Journal:  Am J Trop Med Hyg       Date:  2016-02-22       Impact factor: 2.345

2.  Peripheral neuropathy in leprosy: Clinical manifestations and disability in a Colombian national referral center.

Authors:  Laura Trujillo-Ramirez; María Alejandra Palacios-Ariza; Ivan Pradilla; Luis Arturo Gamboa
Journal:  Dermatol Reports       Date:  2021-08-05

3.  The involvement of endothelial mediators in leprosy.

Authors:  Maria Renata Sales Nogueira; Ana Carla Pereira Latini; Maria Esther Salles Nogueira
Journal:  Mem Inst Oswaldo Cruz       Date:  2016-10-03       Impact factor: 2.743

4.  Leprosy reactions: The predictive value of Mycobacterium leprae-specific serology evaluated in a Brazilian cohort of leprosy patients (U-MDT/CT-BR).

Authors:  Emerith Mayra Hungria; Samira Bührer-Sékula; Regiane Morillas de Oliveira; Lúcio Cartaxo Aderaldo; Araci de Andrade Pontes; Rossilene Cruz; Heitor de Sá Gonçalves; Maria Lúcia Fernandes Penna; Gerson Oliveira Penna; Mariane Martins de Araújo Stefani
Journal:  PLoS Negl Trop Dis       Date:  2017-02-21

Review 5.  Inflammatory Mediators of Leprosy Reactional Episodes and Dental Infections: A Systematic Review.

Authors:  D C B Cortela; A L de Souza Junior; M C L Virmond; E Ignotti
Journal:  Mediators Inflamm       Date:  2015-08-03       Impact factor: 4.711

6.  A new era of diagnostic modalities for type 1 leprosy reactions: Promise for the future.

Authors:  Mary Thomas
Journal:  Indian J Med Res       Date:  2015-12       Impact factor: 2.375

7.  T-cell regulation in Erythema Nodosum Leprosum.

Authors:  Edessa Negera; Stephen L Walker; Kidist Bobosha; Rawleigh Howe; Abraham Aseffa; Hazel M Dockrell; Diana N Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2017-10-09

8.  Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports.

Authors:  Pugazhenthan Thangaraju; Sajitha Venkatesan; Meenalotchini Gurunthalingam; Shoban Babu; Tamilselvan T
Journal:  Rev Soc Bras Med Trop       Date:  2020-09-11       Impact factor: 1.581

9.  Target/therapies for chronic recurrent erythema nodosum leprosum.

Authors:  Pugazhenthan Thangaraju; Shoban Babu Varthya; Sajitha Venkatesan
Journal:  Indian J Pharmacol       Date:  2020-08-04       Impact factor: 1.200

Review 10.  A rare case of type 1 leprosy reactions following tetanus infection in a borderline tuberculoid leprosy patient and a literature review.

Authors:  Chao Shi; Zhi-Chun Jing; De-Gang Yang; Jian-Yu Zhu
Journal:  Infect Dis Poverty       Date:  2018-06-17       Impact factor: 4.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.